ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ADCTLAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ADCTNEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT(NYSE:ADCT) LAUSANNE, Switzerland, Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 29,700 of the...
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
ADCTLAUSANNE, Switzerland, Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
ADCTZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be...
ADC Therapeutics Raises $100M in Private Stock Deal of 13M Shares at $3.5/Share And Warrants To Purchase 15.7M Shares At $3.43/Pre-funded Warrant to Boost Cancer Drug Development
ADCTADC Therapeutics Reports 93% Response Rate in Lymphoma Drug Trial, Including CAR-T Resistant Patients
ADCTRBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target
ADCTADC Therapeutics Q1 Adj. EPS $(0.22) Beats $(0.40) Estimate, Sales $23.03M Beat $17.71M Estimate
ADCTADC Therapeutics Presents Data From LOTIS-7 Phase 1B Clinical Trial Evaluating ZYNLONTA In Combination With Glofitamab In Patients With r/r DLBCL
ADCTEarnings Scheduled For May 14, 2025
ADCTPreview: ADC Therapeutics's Earnings
ADCTADC Therapeutics' Claudin-6 Targeting ADC Shows Strong Single-Agent And Combination Potential In Solid Tumors
ADCTGuggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $7
ADCTHC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target
ADCTADC Therapeutics Says $250.9M In Cash As Of December 31, 2024 Is Expected To Provide Cash Runway Into The Second Half Of 2026
ADCTADC Therapeutics Q4 2024 Adj EPS $(0.25) Beats $(0.41) Estimate, Sales $16.91M Miss $19.01M Estimate
ADCTA Preview Of ADC Therapeutics's Earnings
ADCTCantor Fitzgerald Reiterates Overweight on ADC Therapeuticsto Overweight
ADCTStephens & Co. Maintains Overweight on ADC Therapeutics, Raises Price Target to $8
ADCTADC Therapeutics's Earnings: A Preview
ADCTAnalyst Ratings for ADC Therapeutics
ADCTAnalysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
ADCTUpgrades
Expert Ratings for ADC Therapeutics
ADCTADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter:
Where ADC Therapeutics Stands With Analysts
ADCTOver the past 3 months, 4 analysts have published their opinion on ADC Therapeutics (NYSE:ADCT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Downgrades ADC Therapeutics to Equal-Weight, Lowers Price Target to $11
ADCTHow To Attend ADC Therapeutics Q1 2022 Earnings Conference Call
ADCTADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
How to Attend ADC Therapeutics (ADCT) Conference Call
Follow this link to access the live webcast.
